Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc.verified

CYCC

Price:

$0.315

Market Cap:

$1.98M

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, wh...[Read more]

Industry

Biotechnology

IPO Date

2004-03-16

Stock Exchange

NASDAQ

Ticker

CYCC

The Enterprise Value as of December 2024 (TTM) for Cyclacel Pharmaceuticals, Inc. (CYCC) is -1001529.00

According to Cyclacel Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -1001529.00. This represents a change of -21.44% compared to the average of -1274785.73 of the last 4 quarters.

Cyclacel Pharmaceuticals, Inc. (CYCC) Historical Enterprise Value (quarterly & annually)

How has CYCC Enterprise Value performed in the past?

The mean historical Enterprise Value of Cyclacel Pharmaceuticals, Inc. over the last ten years is 93.45M. The current -1001529.00 Enterprise Value has changed -207.17% with respect to the historical average. Over the past ten years (40 quarters), CYCC's Enterprise Value was at its highest in in the June 2021 quarter at 776.35M. The Enterprise Value was at its lowest in in the December 2022 quarter at -9875370.27.

Quarterly (TTM)
Annual

Average

93.45M

Median

46.25M

Minimum

-11659551.92

Maximum

255.25M

Cyclacel Pharmaceuticals, Inc. (CYCC) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Cyclacel Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 545.53%

Maximum Annual Enterprise Value = 255.25M

Minimum Annual Increase = -1745.51%

Minimum Annual Enterprise Value = -11659551.92

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023-1069323.95-90.83%
2022-11659551.92545.53%
2021-1806198.70-54.53%
2020-3972341.25-1745.51%
2019241.41K-99.74%
201892.25M-47.36%
2017175.26M-31.34%
2016255.25M14.08%
2015223.74M8.45%
2014206.31M-76.63%

Cyclacel Pharmaceuticals, Inc. (CYCC) Average Enterprise Value

How has CYCC Enterprise Value performed in the past?

The current Enterprise Value of Cyclacel Pharmaceuticals, Inc. (CYCC) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

3-year avg

-4845024.86

5-year avg

-3653202.16

10-year avg

93.45M

Cyclacel Pharmaceuticals, Inc. (CYCC) Enterprise Value vs. Peers

How is CYCC’s Enterprise Value compared to its peers?

Cyclacel Pharmaceuticals, Inc.’s Enterprise Value is less than Eliem Therapeutics, Inc. (0), less than Ikena Oncology, Inc. (39.45M), less than Ovid Therapeutics Inc. (67.81M), greater than Connect Biopharma Holdings Limited (-53600395.00), less than Edgewise Therapeutics, Inc. (2.78B), less than Rezolute, Inc. (246.04M), greater than Cyteir Therapeutics, Inc. (-20511738.00), less than XOMA Corporation (288.19M), less than Protagenic Therapeutics, Inc. (2.07M), less than Tempest Therapeutics, Inc. (34.08M), less than OncoVista Innovative Therapies, Inc. (0), less than Neurobiological Technologies, Inc. (0), less than Polydex Pharmaceuticals Limited (0), less than Catalyst Biosciences, Inc. (7.95M), less than Moleculin Biotech, Inc. (1.02B), greater than Pulmatrix, Inc. (-3602106.00), less than Akari Therapeutics, Plc (11.13M), less than NextCure, Inc. (10.90M), less than CytomX Therapeutics, Inc. (4.32M), less than Neoleukin Therapeutics, Inc. (54.54M), greater than Spero Therapeutics, Inc. (-6333315.00), greater than Assembly Biosciences, Inc. (-20633513.00), less than null (68.97M),

Build a custom stock screener for Cyclacel Pharmaceuticals, Inc. (CYCC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cyclacel Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cyclacel Pharmaceuticals, Inc. (CYCC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cyclacel Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Cyclacel Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Cyclacel Pharmaceuticals, Inc. (CYCC)?

What is the 3-year average Enterprise Value for Cyclacel Pharmaceuticals, Inc. (CYCC)?

What is the 5-year average Enterprise Value for Cyclacel Pharmaceuticals, Inc. (CYCC)?

How does the current Enterprise Value for Cyclacel Pharmaceuticals, Inc. (CYCC) compare to its historical average?